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Abstract: Cancer stem cell (CSC) is considered as a cause of cancer recurrence and metastasis. Simultaneously 
CSCs are responsible for the heterogeneous population in tumor tissues due to their differentiation potential. How-
ever, the characterizations of CSCs are still not enough and cancer stem cell lines widely available is desired to be 
established for the advancement of cancer research. In this study, we tried to isolate and characterize stem like 
cells from human glioblastoma cell line U-251MG cells. U-251MG P1 cells, which was previously condensed in the 
presence of hyaluronic acid as CD44 positive population were subjected to single cell isolation procedure. Although 
5 clones were isolated, only one clone exhibited high expression of CD44, Nanog, OCT3/4 and SOX2, and named 
U-251MGSC1. The sphere forming ability of U-251MGSC1 cell was significantly higher than the parental U-251MG 
cells. Tumorigenicity of U-251MG-SC1 cells were higher than that of U-251MG cells. U-251MGSC1 cells exhibited 
higher expression of CD44, SOX2, Nestin and A2B5 than U-251MG cells in vitro and in vivo. The expression of 
GFAP and NF-M was enhanced when the cells were treated with the conditioned medium of U-251MG cells indicat-
ing the potential of differentiation. Sphere forming ability was more efficient than that of U-251MG cells and was 
enhanced in the presence of hyaluronic acid, which enhanced the cell growth as well. U-251MGSC1 cells exhibited 
rapid growth tumor in nude mice and efficient metastatic ability in transmembrane assay when compared with U-
251MG cells. As the result, we concluded U-251MGSC1 cell was a glioblastoma CSC line derived from the parental 
U-251MG cells. U-251MGSC1 cells will be a good tool to develop effective therapeutic agents against CSCs and to 
elucidate the properties of glioma derived CSCs and the mechanism of tumor development in brain.
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Introduction
Studies in 2019 has shown that cancer be- 
came the number one cause of death in 
advanced countries [1]. Current development 
of cancer treatment is highly competitive and 
new therapeutic agents and treatments are 
commercialized around the world. Surgical 
operation, chemo- and radiation-therapy are 
mainly used for cancer treatment (Table 1). 
However, it is sometimes extremely difficult to 
eliminate tumor cells completely resulting in 
the growth of residual cells and the recur- 
rence. CSC is emphasized due to its cells re- 
sistant to chemotherapy and radiation surviv-
ing as a cause of recurrence and metastasis 
and many studies have proved its system [2, 
3]. CSCs have been shown pluripotent, self-
renewing and able to form tumors similar to 
the original one even from a small number of 
cells [4, 5]. Therefore, some researchers con-
sider CSCs should be the potential target of 
treatment against cancer including recurrence 
and metastasis characterizing CSCs in more 
details [6-8]. However, it is still difficult to es- 
tablish CSC lines since the procedures to iso-
late CSCs from cancer cell lines or cancer tis-
sues have not been well established. General- 
ly, cell lines contain heterogeneous population 
of cells. Many cell lines are described to be 
isolated as subclones from their parental cells. 
For instance, NTER2 D1 cells [9, 10] are the 
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Table 1. Features of each cancer treatment method
Therapeutic methods Advantage disadvantage CSC  targetability ref
Chemotherapy Anti-cancer agent ■ Therapeutic effect on systemic cancer ■ Severe side effects
■ Paclitaxel ■ Induction of chemoresistance NS*1 [58]
■ Cisplatin NS [59]
■ Doxorubicin NS [60]
Anti-Cancer stem cell ■ Disperse side effects ■ Changes in normal stem cells to CSC
■ Metformin (Type 2 anti-diabetic) ■ Less chance of developing chemoresistance ■ Induction of toxicity to normal tissues and organs S*2 [61]
■ Mithramycin (RNA synthesis inhibitor) ■ Very effective against cancer metastasis and recurrence ■ Potential increased risk of drug resistance S [61]
■ Expected to cure cancer
Combination ■ Antigen specific ■ Large cost burden
■ Opdivo/Yervoy ■ Disperse side effects ■ Strict attention to dosage and frequency of 
administration
NS [62]
■ Gefitinib/Carboplatin/Pemetrexed ■ Reduces the chance of developing treatment-resistant 
cancer cells
NS [63]
■ Vismodegib (Hedgehog inhibitor)/Gemcitabine S [61]
DDS ■ Reduces side effects ■ Difficulty in technological development
■ Trastuzumab-monomethyl auristatin E conjugate ■ Improves therapeutic effect ■ Long development period and high cost NS [64]
■ Brentuximab Vedotin NS [65]
■ Doxil NS [66]
■ Irinotecan liposomes (Onyvyde) NS [67]
Radiation ■ Gamma knife ■ Less physical burden ■ Side effects due to the irradiation site NS
■ Heavy ion beams ■ Painless
■ BNCT
Surgery ■ Resection ■ Complete cure by cancer tissue resection ■ Heavy burden on the body NS
■ Laparotomy ■ Ineffective for recurrence and metastatic cancer
■ Laparoscopic surgery
*1: Non-specific. *2: Specific.
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subclone of human teratocarcinoma cell line 
NTERA-2 cells [11], which are the subclone of 
human teratocarcinoma cell line Tera-2 [12]. 
Also MCF10A and MCF10F cells were sub-
cloned from human breast epithelial cell line 
MCF-10 cells [13]. This is conceivable if the 
cell lines contain stem cell population, which 
makes heterogeneity as the results of differ- 
entiation.
We have been aiming to discover new thera-
peutic targets that are closely associated with 
recurrence and metastasis. During the course 
of time, we have come across with CSCs, which 
are important in the recurrence and metasta-
sis. However, the difficulty to obtain CSCs has 
been a substantial problem to make the prog-
ress as found in many cases of CSC studies. 
Therefore, we started to establish CSC lines to 
discover the drug targets that are specific to 
CSCs. The first target we focused on was glio-
ma, which has a high recurrence rate and is dif-
ficult to treat. Typical brain tumors include glio-
ma, meningioma, schwannoma, and pituitary 
adenoma, some of which can be cured by surgi-
cal removal, but most are surgically removed 
with additional drug or radiation therapy. Astro- 
cytoma in the category of glioma accounts for 
approximately 20% of brain tumors. Originating 
from astrocytes, which is the main constituent 
cells of the brain, astrocytoma is a malignant 
tumor in almost all cases with a strong charac-
ter to infiltrate the surrounding brain tissue. 
As the result, only surgical resection following 
craniotomy is not sufficient to remove astrocy-
toma completely [14]. Such a highly malignant 
glioma is generally treated with the combina-
tion of surgery, chemotherapy, and radiation 
therapy. However, glioma mortality and recur-
rence rates are very high and patient survival 
is very poor [15]. The prevention and the 
development of effective treatments of glioma 
are under investigation and the etiology is still 
unknown.
In this study, we tried to isolate and estab- 
lish CSC lines from human glioma cell line 
U251MG P1 cells using hyaluronic acid be- 
cause we have already identified the overex-
pression of CD44 in this cell line [16]. Since 
CD44 is well known as a CSC marker, here we 
describe the procedure is efficient to isolate 
CSCs with the self-renewal, differentiation and 
tumorigenic potential.
Materials and methods 
Cell culture
Human brain glioblastoma cell line U-251MG 
[17, 18] was obtained from ATCC (VA). U-251MG 
and U-251MG P1 cells were maintained in 
DMEM with high glucose formula (Wako, Japan) 
containing 10% FBS (Thermo Fisher Scientific, 
MA) and 1% Penicillin-Streptomycin (nacalai 
tesque, Kyoto, Japan) under the atmosphere of 
5% CO2 at 37°C. The effect of 100 µg/mL hyal-
uronic acid sodium salt (Wako, Japan) on the 
growth of the cells were assessed in DMEM 
with high glucose formula containing 10% FBS 
and 1% Penicillin-Streptomycin at 37°C under 
the atmosphere of 5% CO2. The culture medium 
was replaced every 2 days.
Single cell cloning
U-251MG P1 cells were suspended in high glu-
cose DMEM containing hyaluronic acid and 
seeded at 1.0 × 104 cells/mL into a 60-mm cul-
ture dish (Ultra low attachment, Corning, NY) 
and cultured under the atmosphere of 5% CO2 
at 37°C for 10 days to form spheres. These 
spheres were centrifuged at 800 rpm for 3 min 
at 20°C and cultured in high glucose DMEM 
with 10% FBS and 1% Penicillin-Streptomycin 
at 37°C under 5% CO2. After 3 days, cells were 
seeded into 10 96-well plates at 0.5 cells/well. 
Cells grew in each well were detached with 50 
μL of 0.025% trypsin and the reaction was 
stopped by adding 150 μL of culture medium. 
After the cells were centrifuged and cells were 
suspended in 1 mL of culture medium. Then 
the cells were seeded into a well in 24-well 
plate (TPP, Switzerland) and cultured under 5% 
CO2 at 37°C. According to the cell growth cells, 
the sizes of the dishes were scaled up to 12-well 
plate, 6-well plate, 60-mm dish, and 100-mm 
dish (TPP, Switzerland).
Real time PCR
Approximately 1.0 × 106 cells were homoge-
nized in 1 mL of TRIzol® Reagent (Thermo 
Fisher Scientific, MA). After addition of 200 μL 
of chloroform (FUJIFILM, Japan), the solution 
was vortexed for 2 min and then incubated for 
2 min at 25°C. After centrifugation at 12,500 g 
for 15 min at 4°C, the supernatant was trans-
ferred to another 1.5 mL-tube. To remove the 
residual phenol 700 μL of chloroform was 
CSCs from human glioblastoma
444 Am J Cancer Res 2021;11(2):441-457









GAPDH 57 Nanog 63
SOX2 57 CD44 57
c-MYC 60 Nodal 54
OCT3/4 60 Nestin 54
KLF4 57 Olig2 57
added and centrifuged. The resultant superna-
tant was mixed with 250 μL of isopropanol 
(Sigma Aldrich, MO) and left standing at 25°C 
for 10 min to precipitate nucleic acid. After cen-
trifugation at 12,500 g for 10 min at 4°C, the 
precipitate was dissolved in 100 μL of DEPC-
treated water. After adding 10 μL 3 M sodium 
acetate (nacalai tesque, Japan) the nucleic acid 
was precipitated again with 250 μL of ethanol 
(FUJIFILM, Japan) by the incubation at -20°C. 
After centrifuged at 16,000 g for 10 min at 
4°C the pellet was rinsed with 500 μL of 75% 
ethanol. After centrifugation at 7,500 g for 5 
min at 4°C, the supernatant was disposed and 
the pellet was air dried. The pellet was com-
pletely dissolved in 30 μL of DEPC-treated 
water by incubation at 60°C for 10 min (Cool 
Thermo Unit CTU-Neo, TAITEC, Japan) and then 
the concentration of nucleic acid was mea-
sured by NANO VUE (GE Healthcare Japan).
To remove DNA, 3 µg of nucleic acid was treat-
ed with 2 units of DNase I (1 unit/μL, Promega, 
WI) in 20 µL of reaction volume at 37°C for 30 
min. The reaction was stopped with 2.5 µL of 
25 mM EDTA followed by the incubation at 
65°C for 10 min and the residual RNA was pre-
cipitated with ethanol and resolved in 30 µL of 
DEPC-treated water. 
To 2 µg of RNA, 1 μL of 50 µM oligo-dT was 
added and the mixture was incubated at 70°C 
for 5 min and chilled on ice. Then cDNA was 
synthesized with the GoScript™ Reverse Trans- 
cription System (Promega, WI). 
PCR was performed to amplify each target 
gene in a 96-well plate (Light Cycler 480 
Multiwell Plate, Roche). The primers employed 
in this study are summarized in Tables 2 and 
3. Each reaction was composed of 0.8 μL each 
of forward and reverse primers in 10 µM, 10 μL 
of GeneAce SYBER qPCR Mix alpha No ROX 
(NipponGene, Japan) and 6.4 μL of milli-Q wa- 
ter and 2 μL of the cDNA solution. Light Cycler 
480 (Roche, Switzerland) was used for the real 
time measurement. The conditions of reaction 
are enzyme activation at 95°C for 10 min flow- 
ed by 45 cycles of denaturing at 95°C for 30 
sec and polymerase reaction at 60°C for 1 min. 
Flow cytometry
U251MG cells, U251MG P1 cells and U251MG- 
SC1 cells confluent in 60-mm dishes were 
washed with PBS twice and the cells were 
detached with 0.0025% trypsin. After sus- 
pended in 100 µL of PBS containing 10% FBS, 
cells were mixed with 1 μL of Pharmingen™ 
APC Mouse Anti-Human CD44 (Becton, Dic- 
kinson and Company, NJ, 2292642) and 1 μL 
of PE anti-human CD133 (BioLegend®, CA, 
B262394) and incubated on ice for 30 min. 
The cells were then centrifuged at 800 rpm 
for 3 min at 25°C and washed with PBS con-
taining 10% FBS. The cells were finally sus-
pended in 150 μL of PBS containing 10% FBS 
passed through a nylon mesh. An Accuri™ C6 
Plus Flow Cytometer (Becton, Dickinson and 
Company, NJ) was used for the measurement.
Table 2. The list of primers used for rt-qPCR
Target gene name GenBank accession Foward primer (5’→ 3’) Reverse primer (5’→ 3’)
GAPDH NM_001357943.2 CAACGACCACTTTGTCAAGCTC GGTCTACATGGCAACTGTGAGG
SOX2 NM_003106.4 GGGAAATGGGAGGGGTGCAAAAGAGG TTGCGTGAGTGTGGATGGGGATTGGTG
c-MYC NM_002467.6 GCGTCCTGGGAAGGGAGATCCGGAGC TTGAGGGGCATCGTCGCGGGAGGCTG
OCT3/4 NM_002701.6 GACAGGGGGAGGGGAGGAGGTAGG CTTCCCTCCAACCAGTTGCCCCAAAC
KLF4 NM_001314052.2 ATGCTCACCCCACCTTCTTC TTCTCACCTGTGTGGGTTCG
Nanog NM_024865.3 ACCTCAGCTACAAACAGGTGAA AAAGGCTGGGGTAGGTAGGT
Olig2 NM_005806.4 CCGATGACCTTTTTCTGCC ATGACTTGAAGCCACTGCC
CD44 NM_000610.3 TGGGTTCATAGAAGGGCACG AGGTGGAGCTGAAGCATTGAA
Nodal NM_018055.5 AGACATCATCCGCAGCCTACA GACCTGGGACAAAGTGACAGTGAA
Nestin NM_006617.2 ATGCTCCTCTCTCTCTGCTC TTCTTTCTCTACCAACCCCC
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Western blotting
Ten µg of protein from each sample was 
applied to SDS-PAGE and electrophoretically 
transferred to PVDF membrane (Merck Milli- 
pore, MA). Membrane was blocked with 5% 
skim milk and incubated at 4°C overnight with 
anti-GFAP antibody (J0510, Santa Cruz Bio- 
technology, CA) diluted to 1/1000 or anti-β-
actin antibody (4970S, Cell Signaling, MA) 
diluted to 1/1000. After wash with TBST for 3 
times, membrane was incubated with anti-
mouse IgG-HRP (sc-200s, Santa Cruz Biotech- 
nology, CA) diluted to 1/1000 or Anti-rabbit 
IgG-HRP (Cell Signaling, 7074S, diluted to 1/ 
1000). Immunoreactive bands were develop- 
ed with Western Lightning™ Plus-ECL (Perkin 
Elmer, MA) and observed by Light Capture II 
system (ATTO, Tokyo, Japan).
Limiting dilution analysis
U-251MG and U-251MGSC1 cells were sus-
pended in DMEM-High glucose (Wako, Japan) 
with 1% ITS-X (Fujifilm, Japan), 1% L-Glutamine 
(nacalai tesque, Japan), 1% NEAA (Fujifilm, 
Japan), 0.5% beta-mercaptoethanol (Sigma-
Aldrich, MO), 1% Penicillin/Streptomycin and 
100 µg/mL hyaluronic acid sodium salt (Wako, 
Japan). Cells were plated at 20, 10, 5, 2.5, 1.25 
and 0.625 cells/well into a Prime Surface 
96-V-plate (Sumitomo Bakelite, Japan). Then 
the cells were incubated at 37°C under the at- 
mosphere of 5% CO2. After 2 weeks, the num-
ber of wells, in which the sphere formation 
was confirmed, was counted and analyzed as 
previously described [19, 20].
Proliferation assay
We prepared DMEM high glucose supplement-
ed with 10% FBS and 1% penicillin streptomy-
cin with and without hyaluronic acid (100 µg/
mL). After plating 1 × 104 U-251MG cells and 
U-251MGSC1 cells on a 24-well plate, the num-
ber of cells was counted every 2 days from the 
next day up to day 9. All cells got confluent after 
11 days. Sphere formation medium with or 
without hyaluronic acid was prepared and the 
sphere forming ability was compared by the 
Limiting dilution assay. Two weeks after cell 
seeding, the number of spheres were counted. 
The limiting dilution analysis was graphed us- 
ing ELDA software [21, 22]. It is especially suit-
able for analyzing limiting dilution data in stem 
cell research.
Differentiation assay
Approximately 30% confluent U-251MG cells 
were seeded on a 10-cm dish. After 4 days, 
the culture CM was collected and passed 
through a 0.2 µm filter. The CM was supple-
mented up to 10% or 50% in the fresh medium 
of U-251MGSC1 cells. Then the cells were cul-
tured for 2 weeks with medium exchange every 
2-day followed by sufficient passage before 
confluency at 37°C, 5% CO2. The expression 
of each protein were confirmed by immunofluo-
rescent staining. After fixing with 4% parafor-
maldehyde at room temperature for 20 min-
utes, the glass plate were washed 3 times and 
incubated with 0.1% Triton X-100 in PBS at 
room temperature for 10 minutes. After block-
ing with 2% BSA for 1 hr at room temperature, 
the cells were incubated with the primary anti-
bodies overnight at 4°C. The information 
on the primary antibodies is as following. Anti-
GFAP antibody (J0510, Santa Cruz Biotechno- 
logy, CA) (dilution 1:50), anti-Nestin antibody 
(N6413, Sigma Aldrich, MO) (dilution 1:100), 
anti-NF-M antibody (BML-NA1216, Enzo, NY) 
(dilution 1:50) and anti-A2B5 antibody (130-
097-864, Miltenyi Biotec, CA) (dilution 1:50). 
After washing 3 times, the secondary antibody 
was incubated at room temperature for 1 hr. 
Alexa flour488 anti-mouse antibody (A11001, 
invitrogen, MA), Alexa flour488 anti-rabbit anti-
body (A21206, invitrogen, MA) and Alexa 
flour555 anti-rabbit antibody (A21428, invitro-
gen, MA) were used as secondary antibodies. 
Vectashield Hardset (VECTOR, CA) was used for 
DAPI staining.
Animal experiments
The animal experiment was reviewed and ap- 
proved by the ethics for animal experiments at 
the Okayama University under the ID OKU-
2017541. All experiments and the animal care 
were performed following to the policy of 
Okayama University. 10 nude mice (Balb/c-nu/
nu, female, four weeks) were purchased from 
Charles River (Kanagawa, Japan). They fed with 
sterilized food and water during the experi-
ments. 2 × 106 cells were injected subcutane-
ously in mice with 200 μL of Matrigel (Corning, 
USA) in PBS.
At the end of the experiments, all of the mice 
were euthanized by the isoflurane-euthanasia 
method [23]. Briefly, 5% isoflurane (DS Pharma 
animal health, Japan) was exposed to the mice 
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Figure 1. Comparison of stem cell marker expression in 5 cell clones by rt-PCR. SC1, SC2, SC3, SC4, SC5 cells indi-
cate newly isolated 5 clones; U251-MGSC1, U-251MGSC2, U-251-MGSC3, U-251MGSC4, U-251MGSC5. ANOVA was 
employed to confirm the significant difference in each graph. n=3, *P<0.05 and **P<0.01. Relative expressions 
are based on SC5.
for several minutes. And euthanasia was con-
firmed by cervical dislocation.
Immunohistochemistry
First, 5-µm paraffin sections were boiled in 10 
mM Na-Citrate, pH 6.5 for 30 min under high 
pressure [24, 25]. Paraffin or 5-µm frozen sec-
tions of mouse subcutaneous tumors were 
exposed to hydrogen peroxide for 20 min to re- 
duce endogenous peroxidase activity. And they 
exposed to horse serum to block the non-spe-
cific protein binding. Then the sections were 
blocked with 5% skim milk, incubated with anti-
CD44 antibody (ab24504, abcam, CA) diluted 
to 1 µg/mL, Smad2 (D43B4) XP® Rabbit mAb 
(3579s, Cell Signaling) diluted to 1/100 and 
GFAP (2A5) Antibody (Santa Cruz, sc-65343) 
diluted to 1/100 at 4°C overnight. After three 
rinses with PBS, the sections were incubated 
with biotinylated anti-rabbit IgG or a peroxidase 
anti-mouse IgG secondary antibodies (Vectas- 
tain ABC kit, Vector laboratory, CA) at 25°C for 
1 hr. After three rinses in the PBS, color was 
developed by incubation with diaminobenzi- 
dine and H2O2 (Peroxidase substrate kit DAB, 
Vector laboratories, Inc., CA). The results of 
the staining were observed with a microscope 
FSX100 (OLYMPUS, Tokyo, Japan).
Transmembrane assay
Cells in 1.0 × 105 were seeded on ThinCert, 
24-well, cell culture insert, TC pore diameter 
8.0 μm (Greiner Bio-One International, Austria) 
with serum-free DMEM high medium. Then 
500 μL of the DMEM high medium with 10% 
FBS was added in each well. The cells were 
kept cultured for 48 hr at 37°C under 5% CO2. 
The cells, which did not transfer the 
membrane, were removed and the transferred 




First, the spheres of U-251MG P1 cells 
were subjected to single cell isolation to 
obtain 5 cell clones, which were named as 
U-251MGSC1, U-251MGSC2, U-251MGSC3, 
U-251MGSC4, and U-251MGSC5. First, the 
expression CD44 gene in these cells was con-
firmed by RT-PCR (Figure 1). It has been shown 
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that CD44 is related with the malignancy of 
glioblastoma [19, 26, 27]. The expression of 
CD44 was the highest in U-251MGSC1 cells 
among the other clones. Also the expression 
of the stemness markers such as SOX2, 
Nanog, and Oct3/4 genes were assessed and 
U-251MGSC1 cells were found to show the 
highest expression of these genes among the 
cells compared. The gene expression of the 
stemness markers, SOX2 [28, 29], OCT3/4 [30, 
31], Nanog [32, 33], c-Myc [34-36], Olig2 [37, 
38], KLF-4 [39-41] and Nestin [42] were then 
compared between U-251MGSC1 cells and the 
parental cells. As the results, the expression 
of the glioma stem cell marker, Nestin, and 
the stem cell markers, SOX2, OCT3/4 Nanog, 
KLF-4 and c-Myc were found the highest in 
U-251MGSC1 cells when compared with the 
parental cells (Figure 2). The expression of 
KLF-4 was observed high in U-251MG P1 and 
U-251MGSC1 cells when compared with the 
original U-251MG cells. These results indicate 
that U-251MGSC1 cells are found to express 
major stem cell markers in presumably high 
level when compared with the parental cells. 
However, the expression levels of integrin α6 
and L1CAM, which were known as ones of the 
glioma stem cell markers, did not show much 
difference between U-251MGSC1 cells and the 
parental cells (data not shown). In the expres-
sion of L1CAM, there appears some relative 
difference but the expression levels were so 
low that we considered there was little differ-
ence in the expression level between the as- 
sessed cell lines.
Characterization of the isolated clone
Expression of CD44, CD133 and Glial fibrillary 
acidic protein. 
U-251MGSC1 cells were further analyzed by 
flow cytometer comparing the markers CD44 
and CD133. CD133 is a protein belonging to 
the prominin family, also known as PROM1 
(prominin-1) or AC133. CD133 has been sug-
gested to be a cell surface marker for adult 
stem cells and has also been reported as a 
cancer stem cell marker in various human tu- 
mors [43]. Therefore, we assessed CD44 and 
CD133 expression. The population of the cells 
with both CD44 and CD133 positive cells was 
the highest as 42.0% while those of U-251MG 
and U-251MG P1 cells were 29.2% and 26.5%, 
respectively (Figure 3A). Looking into the popu-
lation of CD44high, it was found 5.9%, 1.2% 
and 1.0% in U-251MGSC1, U-251MG P1 and 
U-251MG cells, respectively. It is worthwhile 
noticing that U-251MGSC1 exhibited the high-
est expression of CD44. Since U-251MG cells 
were derived from glioma, the expression of 
Figure 2. Comparison of gene expression between the iso-
lated stem cell model line U-251MG SC1 cell and the pa-
rental original cell lines U-251MG and U-251MG P1 cells. 
The relative expression level was evaluated by rt-qPCR. MG, 
P1, SC1 depict U-251MG, U-251MG P1 and U-251MGSC1 
cell, respectively. A. The gene expression of glioma stem 
cell marker Nestin and stem cell marker Sox2. B. The gene 
expression of stemness markers c-Myc, Oct3/4, LKF4 and 
Nanog. C. The gene expression of Olig2. ANOVA was em-
ployed to confirm the significant difference in each graph. 
n=3, *P<0.05 and **P<0.01.
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Figure 3. Expression of markers for CSC and differentiation. A. Flow cytometric analysis of for CSC markers. The 
vertical and horizontal axes represent CD44 and CD133, respectively. Red numbers in the top right indicate the 
percentage of cells positive for both CD44 and CD133. Red numbers in the boxes indicate the percentage of cells 
with high CD44 expression. B. Western blotting detecting GFAP as the differentiation marker of glial cell. Each lane 
shows extracts from U251MG cells (lane 1), U251MG P1 cells (lane 2), and U251MGSC1 cells (lane 3). ANOVA was 
employed to confirm the significant difference in each graph. n=2, *P<0.01.
glial fibrillary acidic protein (GFAP) was assess- 
ed in U-251MG P1 and U-251MGSC1 cells 
(Figure 3B) (see “Supplementary Figure 1” for 
full-length blot images). As the result, GFAP 
was clearly confirmed only in U-251MG cells 
but not in U-251MGSC1 cells implying U- 
251MGSC1 cells were undifferentiated.
Enhanced sphere forming ability and hyaluro-
nan dependence of U-251MGSC1 cells
U-251MGSC1 cells were assessed for the 
sphere forming ability by limiting dilution meth-
od (Figure 4). When compared with U-251MG 
cells, U-251MGSC1 cells exhibited significantly 
higher sphere-forming ability. 
We assessed the effect of hyaluronan on the 
proliferation of U-251MGSC1 cells. The number 
of U-251MGSC1 cells significantly increased 
in the presence of hyaluronic acid after 5 
days (Figure 5A). On the other hand, hyaluro-
nan did not affect on the proliferation of U- 
251MG cells. We also assessed the effect of 
hyaluronan on the ability of sphere formation. 
In the presence of hyaluronic acid, the sphere-
forming ability of U-251MGSC1 cells was sig- 
nificantly enhanced in the range of 1.3 cells/
well to 5 cells/well (Figure 5B).
Differentiation potential and tumorigenicity in 
vivo of U-251MGSC1 cells
From the results of GFAP expression (Figure 
3B), U-251MG cells exhibited the differentia-
tion which implied the cells secreted some 
factor inducing autocrine differentiation. Th- 
erefore, the conditioned medium (CM) of U- 
251MG cells were used to evaluate the differ-
entiation potential of U-251MGSC1 cells. Since 
we did not know which concentration of condi-
tion medium was appropriate for inducing dif-
ferentiation potential, we first confirmed differ-
entiation potential with 10% and 50% CM of 
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Figure 4. Sphere forming ability of U251MGSC1 cells compared to U251MG cells. Limiting dilution analysis was 
performed to evaluate the ability. The number of wells without spheres was counted where cells were seeded in 16 
wells of 96-well plates. The number of the cells seeded in each 16-well was 20, 10, 5, and 2.5 cells/well, respec-
tively. Each natural logarithm of “negative well number”/16 were plotted as “ln (negative well ratio)” for total num-
ber of cells. The trend line represents the estimated active cell frequency. The dotted lines give the 95% confidence 
interval. Typical spheres observed for U-251MG and U-251MGSC1 cells are shown on the right. A value obtained 
by dividing confidence intervals for 1 by the stem cell frequency indicates that the smaller the value, the higher the 
sphere formation ability.
Figure 5. Hyaluronan-dependency in proliferation and self-renewal of U-251MGSC1 cell. A. Proliferation of U-251MG 
and U-251MGSC1 cells was compared in the presence or absence of hyaluronan. Significant differences were evalu-
ated by ANOVA. *P<0.05. B. Sphere formation of U-251MGSC1 cells in the presence or absence of hyaluronan was 
assessed by limiting dilution analysis. The number of wells without spheres was counted where cells were seeded 
in 16 wells of 96-well plates. The number of the cells seeded in each 16-well was 20, 10, 5, 2.5 and 1.3 cells/
well, respectively. Each natural logarithm of “negative well number”/16 were plotted as “ln (negative well ratio)” for 
total number of cells. The trend line represents the estimated active cell frequency. The dotted lines give the 95% 
confidence interval.
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Figure 6. Differentiation of U-251MGSC1 cells in the presence of the condition medium from U-251MG cells. Im-
munofuluorescent cytochemistry of U-251MGSC1 cells against neural stem cell markers, A2B5 and Nestin (A) and 
neural cell markers, GFAP and NF-M (B) after exposed to 10% and 50% of CM for 2 weeks. 50% CM decreased the 
neural stem cell markers and enhance the neural cell markers suggesting the differentiation. Scale bar =53 µm.
U-251MG cells. As the results, treatment with 
50% CM suppressed the expression of A2B5, a 
ganglioside marker for stem cells [24, 25] and 
Nestin, an intermediate filament protein ex- 
pressed in stem cells of the central nervous 
system [23], down to the level in U-251MG cells 
while 10% CM did not (Figure 6A). Simu- 
ltaneously, the expression of GFAP and neuro-
filament middle (NF-M), a marker of cytoskele-
ton in differentiated and mature neurons [26], 
in U-251MGSC1 cells were found to be en- 
hanced. Nestin and NF-M are the components 
of intermediate filaments, which consist of six 
classes of proteins, as markers of nerve cells, 
unlike microtubules and actin fibers ubiquitous-
ly expressed in cells. As the results, the 50% 
CM enhanced the differentiation of U-251M- 
GSC1 cells to the level as equivalent as that of 
U-251MG cells indicating the differentiation 
potential of U-251MGSC1 cells (Figure 6B).
To assess the tumorigenicity of U-251MGSC1 
cells, 2 × 106 cells were subcutaneously trans-
planted into a nude mouse. After transplanta-
tion, the size of tumor measured up to 8 weeks 
(Figure 7). The tumors of both U-251MG and 
U-251MGSC1 cells started to grow after the 
third week. The growth rate of tumor from U- 
251MGSC1 cells was significantly higher than 
that of tumors made from U-251MG cells.
Immunohistochemistry of the sections from 
the tumors formed in nude mice exhibited 
the immunoreactive CD44 and SOX2 in 
CSCs from human glioblastoma
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Figure 7. Tumorigenic potential of U-251MGSC1 cells. A. U-251MG cells and U-251MGSC1 cells were subcutane-
ously transplanted and the growth of tumor was monitored by the size from week 1 to week 8 after the cells were 
injected into nude mice. The tumor size was the average of the vertical and horizontal diameters. n=8. Significance 
was evaluated by t-test. *, P<0.05; **, P<0.01. Typical tumors in vivo and excised were shown on the right. B. Im-
munohistochemical analyses of the tumors. Paraffin embedded tissue sections were stained for anti-human CD44 
antibody and anti-human SOX2. Frozen sections were analyzed for anti-human GFAP antibody. Maginifications of 
objective lens were × 4 and × 20.
U-251MGSC1 cell derived tumor higher than 
those in U-251MG cell derived tumor. On the 
other hand, immunoreactive GFAP was found 
higher in U-251MG cell derived tumor than in 
U-251MGSC1 cell derived tumor.
Metastatic potential of the cells
In the process of cancer metastasis, cancer 
cell migration and infiltration are extremely 
important processes. Many researchers have 
studied that CSCs take an important role in 
producing cancer metastasis [44, 45]. We in- 
vestigated the metastatic potential of U-251- 
MGSC1 cells and performed transmembrane 
assay (Figure 8). The number of migrated cells 
of U-251MG cells was 46.6 whereas that of 
U-251MGSC1 was 184.8. This result shows 
that U-251MGSC1 cells have four times higher 
migration ability than the parental cells. Thus 
U-251MGSC1 cells were shown to be highly 
metastatic among the cells compared.
Discussion
Previously, we described the population of 
U-251MG P1 cells as the highly condensed 
population with the expression of CD44 and 
stemness markers when they were cultured as 
spheres in the presence of hyaluronic acid. 
CD44 is an adhesion molecule that binds to 
extracellular matrix, including hyaluronan, and 
Figure 8. Metastatic potential of U-251MGSC1 cells. U-251MG cells and U-251MGSC1 cells in serum-free medium 
were seeded in a transmembrane-well and then the number of cells transferred to the serum containing medium 
were counted after 48 hr. n=3. Significance was evaluated by t-test. **, P<0.01. Maginifications of objective lens 
was × 4.
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is used as an important marker in many can- 
cer stem cell studies [46-48]. 
In this paper, we isolated five clones from 
U-251MG cells that grew in hyaluronan depen-
dent manner. As was shown in cancer derived 
cell lines, heterogeneous population is obser- 
ved within the cell line U251MG cells. The iso-
lated five clones demonstrated different ex- 
pression levels of stemness markers suggest-
ing the heterogeneity (Figure 1). Among them 
U-251MGSC1 cells showed the highest ex- 
pression of stemness markers implying the 
highest possibility as the stem-like cells. 
Therefore, we further characterized U-251MG- 
SC1 cells as the candidate of CSCs. And U- 
251MGSC1 cells exhibited the highest expres-
sion stem cell genes when compared with the 
original parental cell lines U-251MG and U- 
251MG P1 (Figure 2). 
SOX2 is known as one of the transcription 
factors, functioning to maintain stemness 
in human embryonic stem cells (hES cells), 
trophoblast stem cells (TS cells), and neural 
stem cells. SOX2 is also known as a glioma 
stem cell marker [49]. Nestin has been report-
ed as a class VI intermediate filament protein 
expressed in stem cells of the central nervous 
system (CNS) [50]. And Nestin is not expressed 
in mature CNS. Therefore, Nestin is used as a 
marker in neural cells derived from hES cells 
and induced pluripotent stem cells. The highest 
expression of SOX2, Nestin, c-MYC, OCT3/4 
and Nanog was recognized in U-251MGSC1 
cells. Regarding KLF4 gene expression, U-251- 
MG P1 showed the highest value, but only 
U-251MGSC1 cells showed high expression in 
all of these four stem cell markers. This indi-
cates that U-251MGSC1 has strong character 
of stem cells. The expression levels of CD44 
and CD133 confirmed by flow cytometry were 
further conceivable to conclude the stemness 
of U-251MGSC1 cells. 
Gliomas are brain tumors that develop from 
glial cells found in the brain and spinal cord. 
GFAP is one of intermediate filament proteins 
and is specifically expressed in cells of the 
astroglial (astrocytic) lineage. Therefore, GFAP 
is widely used as an astrocyte marker in the 
brain, and glioma shows positive GFAP immu-
nostaining [51, 52]. We confirmed the expres-
sion of GFAP by Western blotting in U-251MG 
cells (Figure 3B). Interestingly, the neuronal 
phenotype differentiation was induced in 
U-251MGSC1 cells when treated with 50% CM 
of U-251MG cells (Figure 6A, 6B). This result 
indicates the differentiated phenotype of 
U-251MG cells secrete some differentiation 
factors. Taking these into consideration, we 
concluded that U-251MGSC1 cells had the 
potential of differentiation reside in cancer 
stem cells. Hyaluronan enhanced both prolifer-
ation and sphere formation of U-251MGSC1 
cells indicating the significance of CD44 over-
expression (Figure 5). Hyaluronic acid contrib-
utes to the maintenance and proliferation of 
stem cells when CD44 is overexpressed.
The limiting dilution method was employed to 
assess the ability to form spheres in U-251MG 
and U-251MGSC1 cells since sphere formation 
is considered to demonstrate self-renewal 
capacity [53-55]. As the result, U-251MGSC1 
cells was shown to have self-renewal potential 
as a property of cancer stem cell (Figure 4). 
From the results of sphere formation assay, 
we expected high tumorigenic potential in 
U-251MGSC1 cells. When injected into mice, 
U-251MGSC1 cells showed significant tumori-
genicity distinguished from that of U-251MG 
cells of which tumor growth appeared very slow 
and stopped. 
From these tumors, expression of several 
genes was evaluated in the sections. Since the 
growth of U-251MGSC1 cell is dependent on 
hyaluronic acid, the expression of CD44 in the 
tumor was found overexpressed (Figure 7B). 
The expression of SOX2 was simultaneously 
found in the section of U-251MGSC1 tumor. 
These results are consistent with the results of 
gene expression in vitro (Figure 2). On the other 
hand, GFAP in U-251MGSC1 tumor was low. 
This result also agrees with the result in vitro 
(Figure 3B). These results indicate the tumor 
composed of undifferentiated cells may exhibit 
rapid growth and big size in a short period. 
We confirmed the metastatic ability of U- 
251MGSC1 cells, which is consistent with the 
high metastatic potential of CSCs. Additionally, 
many studies have shown that stem cell mark-
ers such as SOX2, Olig2, and Nestin are also 
involved in cancer metastasis [38, 56, 57]. 
The high metastatic potential of U-251MGSC1 
could be elucidated by the expression of these 
markers although more detailed study, such as 
metastasis in vivo, is required. We are further 
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investigating the characters of U-251MGSC1 
cells defining as CSCs.
Conclusions
In this paper, five different clonal cells were 
isolated from human glioma derived U-251MG 
cells, which consist of heterogeneous popula-
tion of cells, showing different gene expres- 
sion. One of these clones, U-251MGSC1 cell, 
was successfully characterized as CSCs by the 
high expression of stem cell markers, metasta-
sis ability, the sphere forming and differentia-
tion ability as well as tumorigenicity in vivo. The 
growth of U-251MGSC1 cells was dependent 
of hyaluronan due to the overexpression of 
CD44. U-251MGSC1 cells will be a good tool to 
develop effective therapeutic agents against 
CSCs and to elucidate the properties of glioma 
derived CSCs and the mechanism of tumor 
development in brain.
We are further aiming at the establishment of 
CSC lines derived from various cancers such 
as in pancreas, breast, lung and etc. in the 
future. 
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Supplementary Figure 1. Full-length blot images of Figure 3B. Western blotting result of GFAP. Anti-GFAP antibody 
(J0510, Santa Cruz Biotechnology, CA) diluted to 1/1000. Western blotting results of anti-β-actin. Anti-β-actin anti-
body (4970S, Cell Signaling, MA) diluted to 1/1000. Each lane shows extracts from U251MG cells (lane 1), U251MG 
P1 cells (lane 2), and U251MGSC1 cells (lane 3).
